Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib with FLAG chemotherapy in pediatric FLT3-ITD positive relapsed/refractory AML
NCT04240002Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Sep 2020
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Started Sep 2020; status: terminated.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04240002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240002.